TY - JOUR T1 - Identification of shared and differentiating genetic risk for autism spectrum disorder, attention deficit hyperactivity disorder and case subgroups JF - medRxiv DO - 10.1101/2021.05.20.21257484 SP - 2021.05.20.21257484 AU - Manuel Mattheisen AU - Jakob Grove AU - Thomas D Als AU - Joanna Martin AU - Georgios Voloudakis AU - Sandra Meier AU - Ditte Demontis AU - Jaroslav Bendl AU - Raymond Walters AU - Caitlin E Carey AU - Anders Rosengren AU - Nora Strom AU - Mads Engel Hauberg AU - Biao Zeng AU - Gabriel Hoffman AU - Jonas Bybjerg-Grauholm AU - Marie Bækvad-Hansen AU - Esben Agerbo AU - Bru Cormand AU - Merete Nordentoft AU - Thomas Werge AU - Ole Mors AU - David M Hougaard AU - Joseph D Buxbaum AU - Stephen V Faraone AU - Barbara Franke AU - Søren Dalsgaard AU - Preben B Mortensen AU - Elise B Robinson AU - Panos Roussos AU - Benjamin M Neale AU - Mark J Daly AU - Anders D Børglum Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/21/2021.05.20.21257484.abstract N2 - Attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are highly heritable neurodevelopmental disorders with a considerable overlap in their genetic etiology. We dissected their shared and distinct genetic architecture by cross-disorder analyses of large data sets, including samples with information on comorbid diagnoses. We identified seven loci shared by the disorders and the first five genome-wide significant loci differentiating the disorders. All five differentiating loci showed opposite allelic directions in the two disorders separately as well as significant associations with variation in other traits e.g. educational attainment, items of neuroticism and regional brain volume. Integration with brain transcriptome data identified and prioritized several significantly associated genes. Genetic correlation of the shared liability across ASD-ADHD was strong for other psychiatric phenotypes while the ASD-ADHD differentiating liability correlated most strongly with cognitive traits. Polygenic score analyses revealed that individuals diagnosed with both ASD and ADHD are double-burdened with genetic risk for both disorders and show distinctive patterns of genetic association with other traits when compared to the ASD-only and ADHD-only subgroups. The results provide novel insights into the biological foundation for developing just one or both of the disorders and for driving the psychopathology discriminatively towards either ADHD or ASD.Competing Interest StatementBarbara Franke has received educational speaking fees from Medice. In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Sunovion, Supernus and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child's Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of www.adhdinadults.com. The other authors declare no competing interests.Funding StatementThe iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014- 1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"), NIMH (1U01MH109514-01 to ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). Dr. Valodakis was funded by NIMH grant K08MH122911 and the 2020 NARSAD Young Investigator Grant #29350 from the Brain & Behavior Research Foundation. Support for this research was further received by Dr. Cormand from the Spanish 'Ministerio de Ciencia, Innovacion y Universidades' (RTI2018-100968-B-100), 'Ministerio de Economia y Competitividad' 'AGAUR/Generalitat de Catalunya' (2017-SGR-738), the European Union H2020 Program [H2020/2014-2020] under grant agreements #667302 (CoCA), 643051 (MiND) and 728018 (Eat2beNICE), and the ECNP network "ADHD across the lifespan". Dr. Faraone is supported by the European Union's Horizon 2020 research and innovation programme under grant agreements No 667302 and 965381; NIMH grants U01MH109536-01, U01AR076092-01A1, R0MH116037 and 5R01AG06495502; Oregon Health and Science University, Otsuka Pharmaceuticals and Supernus Pharmaceutical Company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Scientific Ethics Committee in Denmark and the Danish Data Protection Agency.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data (i.e. summary statistics) will be made available on the iPSYCH download page (https://ipsych.dk/en/research/downloads/). ER -